Sarepta discusses Exondys 51 sales, DMD pipeline

Sarepta Therapeutics Inc. (NASDAQ:SRPT) soared $6.63 (21%) to $37.89 on Tuesday following a presentation in which President, CEO and CMO Edward Kaye reported initial sales of Exondys 51 eteplirsen and provided an update on the company's Duchenne muscular dystrophy pipeline. The presentation occurred at the JP Morgan Healthcare Conference in San Francisco.

Kaye said Exondys 51 generated $5.4 million in 4Q16 sales and noted that since its launch, more than 250 eligible patients have begun the process of requesting reimbursement for the therapy. ...